Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
出版年份 2018 全文链接
标题
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
作者
关键词
-
出版物
Cancers
Volume 10, Issue 12, Pages 487
出版商
MDPI AG
发表日期
2018-12-05
DOI
10.3390/cancers10120487
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation
- (2018) Isabella Faraoni et al. CANCER LETTERS
- Regulation of DNA repair in the absence of classical non-homologous end joining
- (2018) Youn-Jung Kang et al. DNA REPAIR
- A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors
- (2018) Anjali Shailani et al. MEDICAL ONCOLOGY
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation
- (2018) George E. Ronson et al. Nature Communications
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
- (2018) Stephen J. Pettitt et al. Nature Communications
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP2 mediates branched poly ADP-ribosylation in response to DNA damage
- (2018) Qian Chen et al. Nature Communications
- Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
- (2018) Michael Friedlander et al. BRITISH JOURNAL OF CANCER
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
- (2017) Amit M. Oza et al. GYNECOLOGIC ONCOLOGY
- BRCA1 gene: function and deficiency
- (2017) Miho Takaoka et al. International Journal of Clinical Oncology
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2017) Karoline B. Kuchenbaecker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells
- (2017) Margaret Nieborowska-Skorska et al. JOURNAL OF CLINICAL INVESTIGATION
- Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores
- (2017) Julie Lecarpentier et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
- (2017) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
- (2017) Matthew B. Yurgelun et al. JOURNAL OF CLINICAL ONCOLOGY
- Drugging the Cancers Addicted to DNA Repair
- (2017) Jac A. Nickoloff et al. JNCI-Journal of the National Cancer Institute
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP2 controls double-strand break repair pathway choice by limiting 53BP1 accumulation at DNA damage sites and promoting end-resection
- (2017) Alexis Fouquin et al. NUCLEIC ACIDS RESEARCH
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- PARP1 orchestrates epigenetic events setting up chromatin domains
- (2017) Fabio Ciccarone et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
- (2017) Brian A. Dougherty et al. Oncotarget
- Drugging the Cancers Addicted to DNA Repair
- (2017) Jac A. Nickoloff et al. JNCI-Journal of the National Cancer Institute
- Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors
- (2016) Brennan Decker et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Targeted sequencing ofBRCA1andBRCA2across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
- (2016) C. Winter et al. ANNALS OF ONCOLOGY
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer
- (2016) Ozkan Ozden et al. Scientific Reports
- BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib
- (2015) Isabella Faraoni et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Poly-ADP-ribosylation signaling during DNA damage repair
- (2015) Gyula Timinszky Frontiers in Bioscience-Landmark
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
- (2015) Maria Teresa Esposito et al. NATURE MEDICINE
- PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma
- (2015) Jara Majuelos-Melguizo et al. Oncotarget
- BRCA1andBRCA2germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts
- (2014) Aimee L. Lucas et al. CANCER
- PARP inhibitors in ovarian cancer: Current status and future promise
- (2014) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression
- (2014) X. Wei Meng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways
- (2014) Carole Beck et al. NUCLEIC ACIDS RESEARCH
- PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair
- (2014) Y. Hu et al. Cancer Discovery
- The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc
- (2014) John R. Prensner et al. NEOPLASIA
- Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
- (2013) Mo Li et al. CANCER CELL
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
- (2013) Kathryn P. Pennington et al. CLINICAL CANCER RESEARCH
- Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies
- (2013) T. J. Gaymes et al. HAEMATOLOGICA
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Synthetic lethality between CCNE1 amplification and loss of BRCA1
- (2013) D. Etemadmoghadam et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Touching base with PARPs: moonlighting in the repair of UV lesions and double-strand breaks
- (2013) Alex Pines et al. TRENDS IN BIOCHEMICAL SCIENCES
- Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells
- (2013) Fengfeng Cai et al. TUMOR BIOLOGY
- A Comprehensive Focus on Global Spectrum ofBRCA1andBRCA2Mutations in Breast Cancer
- (2013) Fatemeh Karami et al. Biomed Research International
- PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets
- (2013) Girish M. Shah et al. Frontiers in Oncology
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases
- (2011) Isabelle Cousineau et al. MOLECULAR GENETICS AND GENOMICS
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Germline mutations in RAD51D confer susceptibility to ovarian cancer
- (2011) Chey Loveday et al. NATURE GENETICS
- Mutations in BRIP1 confer high risk of ovarian cancer
- (2011) Thorunn Rafnar et al. NATURE GENETICS
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo
- (2010) Pierfrancesco Tassone et al. CANCER BIOLOGY & THERAPY
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Development and implementation of a national telehealth project for long-term care: A preliminary study
- (2010) Min-Huei Hsu et al. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- (2010) Yvette Drew et al. JNCI-Journal of the National Cancer Institute
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- The DNA Damage Response: Making It Safe to Play with Knives
- (2010) Alberto Ciccia et al. MOLECULAR CELL
- miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
- (2010) Patryk Moskwa et al. MOLECULAR CELL
- Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene
- (2010) Alfons Meindl et al. NATURE GENETICS
- Rapid Recruitment of BRCA1 to DNA Double-Strand Breaks Is Dependent on Its Association with Ku80
- (2008) L. Wei et al. MOLECULAR AND CELLULAR BIOLOGY
- Effect ofBRCA1/2Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer
- (2007) Angela Chetrit et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started